Located at the Valld’Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo, ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. All three sections are included within the Functional Validation & Preclinical Research (FVPR) of CIBBIM-Nanomedicine.
This unit is leadedby Dr. Ibane Abasolo (Head of FVPR) and supervised by the directorof CIBBIM-Nanomedicine, Dr. Simó Schwartz Jr. Its mission is to offer products and services for the preclinical proof-of-concept validation of therapeutic compounds and biomarkers with potential clinical applications. One of the distinguishing features of this unit is that basic preclinical studies including toxicology, histopathology and efficacy treatments are complemented with non-invasive optical imaging technologies. In vivo bioluminescence and fluorescence imaging allows monitoring of living mice longitudinally, offering real time insight into treatment efficacy, whole-body biodistribution and target mechanisms. Although in Spain there are other institutions with similar equipment, this is the only case in which imaging services can be combined with specifically devoted animal models.
NANBIOSIS-U20 Scientific Director, Simó Schwartz, speaks about Nanomedicine in an interview publish in http://www.quimicaysociedad.org. NANBIOSIS is an Singular Scientific Technological Infrastructure (ICTS) that provides a complete service for the production and characterization of nanomaterials, biomaterials and systems in biomedicine, including the design and production of biomaterials and nanomaterials and their nanoconjugates, and the characterization of these bio-/nanomaterials, tissues and medicals devices from a physic-chemical, functional, toxicological and biological (including preclinical validation) point of view, focused also on biomedical applications such as: IVDs, biosensors, regenerative medicine, drug delivery, therapeutic agents or MRI contrast agents and medical devices. Question: First of all,[...]
The EU-NCL network will finance a project of nanomedicine for prostate cancer cordinated by Simó Schwartz and Ibane Abasolo, NANBIOSIS-U20 Director and Coordinator. The European Nanomedicine Characterisation Laboratory (EU-NCL) has selected a project from VHIR intended to develop a therapeutic nanoconjugate that improves the treatment of prostate cancer. Among all proposals presented to EU-NCL, only this one in Spain is part of a small group chosen to carry out the necessary tests to move the product into clinical practice, which makes Vall d’Hebron Campus a leading nanomedicine hospital with capacity to generate and validate therapeutic nanoconjugates and nanomedicines. The main difficulty in this[...]
The ESNAM / ISNM Summer School is co-organized by ESNAM and CIBER-BBN (led by Simó Schwartz, president of ESNAN and transfer manager of CIBER-BBN as well as Scientific Director of Unit 20 of NANBIOSIS). The summer school is aimed at any student or professional interested in nanomedicine. It will count on the presence of speakers of recognized prestige in the area, among which are the Scientific Directors and Coordinators of several of the units of NANBIOSIS. The ESNAM / ISNM Summer School will be held on 28-29 September 2017 at the Hospital Vall d’Hebron, Barcelona The registration deadline with accommodation included ends on[...]
Last November took place in CosmoCaixa, Barcelona, the B-Debate Days Imaging for Life. Molecules from Diagnostics and Therapy. The event, organized by B·Debate (an initiative of Biocat and “la Caixa” Foundation), IBB and LJS, was focussed on Biomolecular Imaging, with emphasis on molecular, cellular, tissular and small animal research, as well as biomedical applications, including noninvasive diagnostics, image guided surgery, multimodal imaging and theranostics. Scientists of NANBIOIS Unit 20 and 25 were invited to participate as guest lecturers: -Simó Schwartz, Scientific Director of Unit 20: New bioluminescent models to target cancer stem cells with nanomedicine. -Ana Paula Candiota, Scientific Coordinator of[...]
The objectives of ESNAM are to promote nanomedicine research and facilitate the exchange of knowledge among its members (currently, about 800 members). According to Dr. Simó Schwartz “the dissemination of specialized infrastructure in nanomedicine, like NANBIOSIS, among members of the society and its utilities is also an object of ESNAM. This is intended to strengthen European technological capabilities, use, and improvement of clinical transfer”. Society members represent different sectors of the scientific community: doctors, biologists, chemists, pharmacists, physical …. The technical office of the ESNAM in Barcelona is located in the Vall d’Hebron Hospital and is coordinated by Aida Castellanos,[...]
Unit 1 of NANBIOSIS, Protein Production Platform (PPP), Unit 3, Synthesis of Peptides, Unit 20, In Vivo Experimental Platform and Unit 6, Biomaterial Processing and Nanostructuring Unit, have jointly developed the research conducted in relation with a CO2-based methodology for the one-step production of protein-nanoliposome conjugates as bio-active nanomaterials with therapeutic interest. The results have been published in Advanced Healthcare Materials: http://www.ncbi.nlm.nih.gov/pubmed/26890358 “a-Galactosidase A Loaded Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration I. Cabrera, I. Abasolo, J. L. Corchero, E. Elizondo, P. Rivera, E. Moreno, J. Faraudo, S. Sala, D. Bueno, E. González-Mira, M. Rivas, M. Melgarejo, D. Pulido,[...]